. 2025 Jan 1;16(2):622–628. doi: 10.7150/jca.103097

Table 2.

Stratification analysis for the association between NSUN1 gene polymorphisms and neuroblastoma susceptibility

Variables	rs11834074 (cases/controls)		AOR (95% CI) ^a	P ^a	rs3764909 (cases/controls)		AOR (95% CI) ^a	P ^a	Protective genotypes (cases/controls)		AOR (95% CI) ^a	P ^a
	GG	GA/AA			CC	CA/AA			0-1	2
Age, month
≤18	74/71	65/68	0.92 (0.57-1.47)	0.712	62/59	77/80	0.91 (0.57-1.47)	0.710	89/88	50/51	0.97 (0.59-1.58)	0.897
>18	126/153	137/181	0.92 (0.67-1.27)	0.609	113/141	150/193	0.97 (0.70-1.34)	0.853	151/184	112/150	0.91 (0.66-1.26)	0.569
Gender
Females	94/110	97/115	0.99 (0.67-1.46)	0.952	87/94	104/131	0.86 (0.58-1.27)	0.439	111/132	80/93	1.03 (0.69-1.52)	0.902
Males	106/114	105/134	0.84 (0.58-1.22)	0.360	88/106	123/142	1.04 (0.72-1.52)	0.819	129/140	82/108	0.82 (0.57-1.20)	0.308
Sites of origin
Adrenal gland	46/224	47/249	0.91 (0.58-1.42)	0.678	40/200	53/273	0.98 (0.62-1.53)	0.917	57/272	36/201	0.84 (0.53-1.33)	0.448
Retroperitoneal	85/224	82/249	0.87 (0.61-1.24)	0.438	76/200	91/273	0.88 (0.62-1.25)	0.468	101/272	66/201	0.89 (0.62-1.27)	0.510
Mediastinum	56/224	64/249	1.03 (0.69-1.54)	0.897	46/200	74/273	1.18 (0.78-1.78)	0.430	68/272	52/201	1.03 (0.69-1.55)	0.874
Others	10/224	8/249	0.73 (0.28-1.88)	0.510	10/200	8/273	0.58 (0.22-1.49)	0.255	11/272	7/201	0.88 (0.33-2.31)	0.793
Clinical stages
I+II+4s	80/224	93/249	1.04 (0.73-1.48)	0.831	70/200	103/273	1.10 (0.77-1.57)	0.605	102/272	71/201	0.92 (0.65-1.32)	0.664
III+IV	89/224	74/249	0.74 (0.52-1.06)	0.103	78/200	85/273	0.80 (0.56-1.15)	0.228	100/272	63/201	0.84 (0.59-1.22)	0.365

OR, odds ratio; CI, confidence interval.

^a Adjusted for age and gender, omitting the correspondence factor.